Clinical Trial Update: Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients [Phase 3]

View source ↗

Summary

This entry describes a Phase 3 trial comparing elranatamab plus lenalidomide consolidation and/or elranatamab maintenance versus standard of care after D-VRd in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Intergroupe Francophone du Myelome | Conditions: Multiple Myeloma, Newly Diagnosed | Phase 3 | Status: RECRUITING